Skip to main content

Table 6 Items included in the questionnaire and results

From: Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report

   Mean Median Interquartile range Above the median Result
51 Treatment of rhinitis in patients with asthma contributes to the improvement of bronchial symptoms 7.7 8 2 7.5 Agreement
52 Treatment of rhinitis in patients with asthma reduces socio-economic costs 7.93 8 1.5 12.5 Agreement
53 Treatment of rhinitis in patients with asthma improves their quality of life 8.33 8.5 1 2.5 Agreement
54 Allergen avoidance in ARD is the first line of treatment for all patients, regardless of severity 7.8 8 2 12.5 Agreement
55 Maintenance drug therapy must be recommended, at least as long as the patient is exposed to the causative airborne allergen 7.35 8 2 22.5 Agreement
56 Maintenance drug therapy can be extended for as long as is necessary to achieve good control of the disease 8.38 9 1 0 Agreement
57 Adjustment of treatment in ARD patients must consider the “maximum severity reached in previous allergenic exposures” 7.28 8 1 15 Agreement
58 Treatment of patients who experienced severe symptoms in previous allergenic exposures may not follow the step-up strategy recommended by consensus guidelines and can begin with a higher therapeutic step 7.85 8 2 7.5 Agreement
59 The doses used in the pharmacological treatment of ARD patients may be greater than those commonly used in non-allergic patients 6.23 7 3 42.5 No consensus
60 The prognosis of ARD depends on the presence of polysensitization 6.6 7 2 30 Agreement
61 The treatment strategy in polysensitized patients consists of adapting maintenance treatment to the relevant allergen 6.95 7 1 22.5 Agreement
62 Failure of drug therapy is not a prerequisite for AIT in patients with ARD 8.35 9 1 2.5 Agreement
63 AIT is most effective in early stages of ARD 7.95 8 1.5 10 Agreement
64 Most patients will benefit from treatment with AIT to slow disease progression 7.75 8 2 15 Agreement
65 Most patients with ARD will benefit from treatment with AIT to reduce the severity of symptoms and use of medication and to improve quality of life 7.95 8 1.5 7.5 Agreement
66 Unlike pharmacological treatment, AIT improves the prognosis of ARD 8.08 8 1 5 Agreement
67 AIT decreases the occurrence of new sensitizations in ARD patients 6.53 7 3 37.5 No consensus
68 AIT can prevent the development of bronchial symptoms in patients with rhinoconjunctivitis 7.85 8 2 10 Agreement
69 In ARD patients, identification of the airborne allergen that is clinically responsible for symptoms is essential when attempting to establish the indication of AIT 8.7 9 0.5 0 Agreement
70 The composition of immunotherapy in polysensitized ARD patients must be based on a selection of the relevant allergen(s) according to the patient’s clinical and sensitization profile 8.3 9 1 2.5 Agreement
71 A sufficient dose of each allergen must be ensured in AIT with mixtures of allergens in polysensitized ARD patients 8.23 8.5 1 5 Agreement
  1. Treatment–avoidance, drug treatment and allergen immunotherapy (AIT)
  2. ARD allergic respiratory disease, AIT allergen immunotherapy